Pancreatic Cancer Research

ResearcherGeorgetown UniversityActive in the last 2 years

Mariaelena Pierobon

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2084-1029; OpenAlex author ID A5073337554; NIH RePORTER profile ID 12040235. Sources: OpenAlex.

Their work

Papers
13 (first author 0, last author 1)
Trials
0
Grants
1
Labs led
0
Collaborators
53
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper · 2020: 2 papers · 2021: 2 papers · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 3 papers · 2026: 2 papers, 1 grant

Papers 13

  1. Interruption of cross-communication pathways alters the immune cell signature of pancreatic cancer and decreases tumor growth. Last author DOI 10.1186/s12964-026-02676-8↗
  2. Vertical inhibition of the autophagy pathway impairs growth and enhances sensitivity to mTORC1 inhibition in pancreatic ductal adenocarcinoma Co-author DOI 10.64898/2026.06.28.734981↗
  3. Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer. Co-author DOI 10.1126/scisignal.adu7145↗
  4. Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Ca… Co-author DOI 10.1158/0008-5472.can-25-1507↗
  5. Downregulation of the CCK-B Receptor in Pancreatic Stellate Cells Blocks Molecular Proliferative Pathways and Increases Apoptosis to Decrease Pancreatic Cancer… Co-author DOI 10.3390/ijms262311699↗
  6. Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-22-0391↗
  7. Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy Inhibitors. Co-author DOI 10.1158/0008-5472.can-21-1443↗
  8. CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. Co-author DOI 10.1016/j.celrep.2021.110060↗
  9. The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer. Co-author DOI 10.1016/j.jbc.2021.101335↗
  10. Author Correction: Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Co-author DOI 10.1038/s41591-020-0947-8↗
  11. Atypical KRAS G12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-19-1006↗
  12. Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Co-author DOI 10.1038/s41591-019-0368-8↗
  13. Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression. Co-author DOI 10.1016/j.ccell.2015.11.011↗

Grants 1

  1. The CCK-B receptor signaling pathway as a driver of pancreatic cellular plasticity and carcinogenesis R01CA277680↗

Closest collaborators

The 25 strongest of 53 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jill P Smith · 1 shared paper, 1 shared grant, 2026 · strength 1.50
  2. Kirsten L. Bryant · 10 shared papers, 2016–2026 · strength 1.24
  3. Clint A. Stalnecker · 8 shared papers, 2019–2026 · strength 1.12
  4. Adrienne D. Cox · 10 shared papers, 2016–2025 · strength 1.08
  5. Channing J. Der · 10 shared papers, 2016–2025 · strength 1.08
  6. Jennifer E. Klomp · 7 shared papers, 2019–2025 · strength 0.73
  7. Bjoern Papke · 7 shared papers, 2019–2023 · strength 0.67
  8. Andrew M. Waters · 6 shared papers, 2019–2025 · strength 0.63
  9. J. Nathaniel Diehl · 6 shared papers, 2019–2025 · strength 0.60
  10. Kristina Drizyte‐Miller · 4 shared papers, 2021–2025 · strength 0.59
  11. Emanuel F. Petricoin · 7 shared papers, 2016–2022 · strength 0.59
  12. Jonathan M. DeLiberty · 4 shared papers, 2020–2026 · strength 0.56
  13. Emanuel F. Petricoin · 3 shared papers, 2023–2025 · strength 0.50
  14. Ryan N. Robb · 2 shared papers, 2025–2026 · strength 0.45
  15. Mallory K. Roach · 2 shared papers, 2025–2026 · strength 0.45
  16. Craig M. Goodwin · 4 shared papers, 2020–2023 · strength 0.43
  17. A. Cole Edwards · 2 shared papers, 2022–2025 · strength 0.31
  18. Naim U. Rashid · 2 shared papers, 2021–2025 · strength 0.29
  19. Priya S. Hibshman · 2 shared papers, 2021–2025 · strength 0.29
  20. Lee M. Graves · 2 shared papers, 2021–2025 · strength 0.29
  21. Jill Palmer Smith · 1 shared paper, 2025 · strength 0.27
  22. Miranda Ortega · 1 shared paper, 2025 · strength 0.27
  23. Jack C. Drda · 1 shared paper, 2026 · strength 0.24
  24. G. Aaron Hobbs · 3 shared papers, 2019–2020 · strength 0.22
  25. Tikvah K. Hayes · 3 shared papers, 2016–2020 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.